- Home
- ANNX
ANNX
Annexon Inc.
as of 03-19-2026 3:42pm EST
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 730.4M | IPO Year: | 2020 |
| Target Price: | $16.50 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | annual |
| EPS: | -1.08 | EPS Growth: | 42.94 |
| 52 Week Low/High: | $1.28 - $7.18 | Next Earning Date: | 03-05-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -5.02 | Index: | N/A |
| Free Cash Flow: | -118021000.0 | FCF Growth: | N/A |
AI-Powered ANNX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Annexon Inc. (ANNX)
Director
Avg Cost/Share
$5.67
Shares
8,000
Total Value
$45,360.00
Owned After
62,405
SEC Form 4
EVP & CHIEF FINANCIAL OFFICER
Avg Cost/Share
$5.42
Shares
5,565
Total Value
$30,162.30
Owned After
170,700
SEC Form 4
EVP & CHIEF BUSINESS OFFICER
Avg Cost/Share
$5.42
Shares
4,339
Total Value
$23,517.38
Owned After
182,625
SEC Form 4
CHIEF MEDICAL OFFICER
Avg Cost/Share
$5.43
Shares
5,820
Total Value
$31,602.60
Owned After
123,582
SEC Form 4
EVP & CHIEF SCIENTIFIC OFFICER
Avg Cost/Share
$5.43
Shares
5,894
Total Value
$32,004.42
Owned After
180,093
SEC Form 4
EVP & CHIEF INNOVATION OFFICER
Avg Cost/Share
$5.42
Shares
5,566
Total Value
$30,167.72
Owned After
154,161
SEC Form 4
EVP & CHIEF FINANCIAL OFFICER
Avg Cost/Share
$5.11
Shares
7,851
Total Value
$40,118.61
Owned After
170,700
SEC Form 4
EVP & CHIEF BUSINESS OFFICER
Avg Cost/Share
$5.10
Shares
6,225
Total Value
$31,747.50
Owned After
182,625
SEC Form 4
CHIEF MEDICAL OFFICER
Avg Cost/Share
$5.10
Shares
5,290
Total Value
$26,979.00
Owned After
123,582
SEC Form 4
EVP & CHIEF SCIENTIFIC OFFICER
Avg Cost/Share
$5.10
Shares
5,290
Total Value
$26,979.00
Owned After
180,093
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Carson William H. | ANNX | Director | Mar 10, 2026 | Buy | $5.67 | 8,000 | $45,360.00 | 62,405 | |
| Lew Jennifer | ANNX | EVP & CHIEF FINANCIAL OFFICER | Mar 2, 2026 | Sell | $5.42 | 5,565 | $30,162.30 | 170,700 | |
| Overdorf Michael | ANNX | EVP & CHIEF BUSINESS OFFICER | Mar 2, 2026 | Sell | $5.42 | 4,339 | $23,517.38 | 182,625 | |
| Dananberg Jamie | ANNX | CHIEF MEDICAL OFFICER | Mar 2, 2026 | Sell | $5.43 | 5,820 | $31,602.60 | 123,582 | |
| ARTIS DEAN RICHARD | ANNX | EVP & CHIEF SCIENTIFIC OFFICER | Mar 2, 2026 | Sell | $5.43 | 5,894 | $32,004.42 | 180,093 | |
| Yednock Ted | ANNX | EVP & CHIEF INNOVATION OFFICER | Mar 2, 2026 | Sell | $5.42 | 5,566 | $30,167.72 | 154,161 | |
| Lew Jennifer | ANNX | EVP & CHIEF FINANCIAL OFFICER | Feb 18, 2026 | Sell | $5.11 | 7,851 | $40,118.61 | 170,700 | |
| Overdorf Michael | ANNX | EVP & CHIEF BUSINESS OFFICER | Feb 18, 2026 | Sell | $5.10 | 6,225 | $31,747.50 | 182,625 | |
| Dananberg Jamie | ANNX | CHIEF MEDICAL OFFICER | Feb 18, 2026 | Sell | $5.10 | 5,290 | $26,979.00 | 123,582 | |
| ARTIS DEAN RICHARD | ANNX | EVP & CHIEF SCIENTIFIC OFFICER | Feb 18, 2026 | Sell | $5.10 | 5,290 | $26,979.00 | 180,093 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q3 Q3 2025 Earnings
8-K BUY Nov 10, 2025 · 100% conf.
Q3 2025 Earnings
8-K BUYNov 10, 2025 · 100% conf.
1D
+7.21%
$3.19
Act: -0.34%
5D
+14.53%
$3.41
Act: +1.34%
20D
+4.40%
$3.11
Act: +63.09%
8-K
false000152811500015281152025-11-102025-11-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025
ANNEXON, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-39402
27-5414423
(State or other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)
1400 Sierra Point Parkway, Bldg C, Suite 200 Brisbane, California 94005 (Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (650) 822-5500 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
ANNX
The Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On November 10, 2025, Annexon, Inc. (the “Company”) announced certain financial results for the third quarter ended September 30, 2025. A copy of the Company’s press release, titled “Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones” is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits. (d)Exhibits.
Exhibit
Description
99.1
Press Release, dated November 10, 2025, titled “Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones”
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 10, 2025
Annexon, Inc.
By:
/s/ Jennifer Lew
Jennifer Lew
Executive Vice President and Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 14, 2025
Q2 2025 Earnings
8-KAug 14, 2025
8-K
false000152811500015281152025-08-142025-08-14
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025
ANNEXON, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-39402
27-5414423
(State or other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)
1400 Sierra Point Parkway, Bldg C, Suite 200 Brisbane, California 94005 (Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (650) 822-5500 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
ANNX
The Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On August 14, 2025, Annexon, Inc. (the “Company”) announced certain financial results for the second quarter ended June 30, 2025. A copy of the Company’s press release, titled “Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones” is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits. (d)Exhibits.
Exhibit
Description
99.1
Press Release, dated August 14, 2025, titled “Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones”
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 14, 2025
Annexon, Inc.
By:
/s/ Jennifer Lew
Jennifer Lew
Executive Vice President and Chief Financial Officer
2025 Q1 Q1 2025 Earnings
8-K May 12, 2025
Q1 2025 Earnings
8-KMay 12, 2025
8-K
false000152811500015281152025-05-122025-05-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025
ANNEXON, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-39402
27-5414423
(State or other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)
1400 Sierra Point Parkway, Bldg C, Suite 200 Brisbane, California 94005 (Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (650) 822-5500 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
ANNX
The Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On May 12, 2025, Annexon, Inc. (the “Company”) announced certain financial results for the first quarter ended March 31, 2025. A copy of the Company’s press release, titled “Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones” is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits. (d)Exhibits.
Exhibit
Description
99.1
Press Release, dated May 12, 2025, titled “Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones”
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 12, 2025
Annexon, Inc.
By:
/s/ Jennifer Lew
Jennifer Lew
Executive Vice President and Chief Financial Officer
Compare ANNX vs Leading Stocks
See how ANNX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ANNX Annexon Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.